New combo aims to keep leukemia at bay after remission

NCT ID NCT07244367

Recruiting now Disease control Sponsor: Sohag University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of two drugs (venetoclax and low-dose cytarabine) can help adults with acute myeloid leukemia (AML) stay in remission longer. Participants are 18–60 years old, have achieved complete remission after initial chemotherapy, and are not able to get a bone marrow transplant right away. The goal is to see if this maintenance therapy delays relapse and improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloblastic leukemia with maturation acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKAEMIA (AML)

Contacts and locations

Locations

Sohag university
RECRUITING

Sohag, Egypt
Sohag university hospital
RECRUITING

Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.